Summary

Market Overview
The United States CAR-T Cell Therapy Market was valued at USD 3.25 Billion in 2024 and is projected to reach USD 5.72 Billion by 2030, growing at a CAGR of 9.85% during the forecast period. CAR-T (Chimeric Antigen Receptor T-cell) therapy represents a rapidly expanding segment within immuno-oncology, marked by transformative advances in biotechnology and cell engineering. This therapy involves modifying a patient’s T-cells to express receptors targeting specific cancer antigens, enhancing the immune system’s ability to eliminate malignant cells. The U.S. market has witnessed substantial growth, largely due to the effectiveness of CAR-T therapies in treating hematologic malignancies such as large B-cell lymphoma, leukemia, and multiple myeloma. As technological advancements continue and the therapy's use extends to new indications and patient populations, CAR-T therapy is becoming an integral component of cancer treatment. With increasing regulatory approvals and progress in manufacturing and scalability, the market is expected to remain on a strong upward trajectory, despite challenges around pricing and access.
Key Market Drivers
Increasing Incidence of Cancer
The growing prevalence of cancer is a significant factor driving the expansion of the U.S. CAR-T Cell Therapy Market. In 2025, approximately 2,041,910 new cancer cases are projected to be diagnosed in the United States, with an estimated 618,120 cancer-related deaths. Among children and adolescents aged 0 to 19, nearly 14,690 new cancer cases are expected, with 1,650 anticipated fatalities. As the number of cancer diagnoses rises, so does the demand for advanced, targeted therapies like CAR-T. This treatment has shown remarkable success, particularly for patients with hematologic malignancies that are unresponsive to conventional therapies such as chemotherapy or radiation. CAR-T cell therapy offers a personalized and highly targeted approach that modifies a patient’s own immune cells to attack cancer. With growing awareness and clinical success, CAR-T is increasingly being adopted as a preferred treatment option in cases where traditional approaches have failed, supporting its continued market expansion.
Key Market Challenges
High Cost and Accessibility Issues
The high cost of CAR-T therapy remains one of the most pressing challenges impacting market growth. A single treatment can range from USD 373,000 to USD 500,000, depending on the specific therapy and healthcare provider. The high expense stems from the complex, individualized manufacturing process involving the extraction, genetic modification, and reinfusion of a patient’s T-cells. While insurance coverage for CAR-T therapies is increasing, many patients still face substantial out-of-pocket expenses, creating a significant access barrier. Healthcare institutions may also struggle with reimbursement and budgeting concerns, especially given the high upfront costs. This can limit patient access and place strain on treatment centers. Manufacturers face the dual challenge of maintaining innovation and cost-effectiveness while addressing market expectations for affordable care. Although the therapy’s effectiveness is widely recognized, its long-term sustainability is questioned due to its pricing and accessibility limitations.
Key Market Trends
Expansion of CAR-T Applications to Solid Tumors
A prominent trend shaping the future of the U.S. CAR-T Cell Therapy Market is the exploration of CAR-T applications beyond hematologic cancers to include solid tumors. Currently, CAR-T therapies are primarily used for blood cancers like leukemia and lymphoma. However, efforts are underway to adapt this technology for solid tumors, including breast, lung, and pancreatic cancers, which collectively represent about 90% of cancer cases. This trend significantly expands the addressable market and creates new growth opportunities. Pharmaceutical companies and research institutions are focusing on developing CAR-T cells capable of overcoming the immunosuppressive tumor microenvironment and targeting solid tumor-specific antigens. Innovations that enhance the infiltration, survival, and persistence of CAR-T cells in solid tumors are essential to unlocking these new therapeutic avenues. Successful clinical translation of these therapies could mark a major milestone in cancer treatment and reshape the oncology landscape.
Key Market Players
• Gilead Sciences, Inc (US)
• Novartis United States
• AbbVie Inc.
• Myriad Genetics
• NeoGenomics Laboratories
• Intellia Therapeutics (US)
• Agilent Technologies, Inc. (US)
• Abcam plc.
• Bio-Techne (ExoDx)
• Sangamo Therapeutics, Inc. (US)
Report Scope:
In this report, the United States CAR-T Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• United States CAR-T Cell Therapy Market, By Product:
o Abecma (idecabtagene vicleucel)
o Breyanzi (lisocabtagene maraleucel)
o Carvykti (ciltacabtagene autoleucel)
o Kymriah (tisagenlecleucel)
o Tecartus (brexucabtagene autoleucel)
o Yescarta (axicabtagene ciloleucel)
o Others
• United States CAR-T Cell Therapy Market, By Disease:
o Leukemia
o Lymphoma
o Multiple Myeloma
o Others
• United States CAR-T Cell Therapy Market, By End User:
o Hospitals
o Cancer Treatment Centers
• United States CAR-T Cell Therapy Market, By Region:
o Northeast
o Midwest
o South
o West
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the United States CAR-T Cell Therapy Market.
Available Customizations:
United States CAR-T Cell Therapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. United States CAR-T Cell Therapy Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Kymriah (tisagenlecleucel), Tecartus (brexucabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Others)
5.2.2. By Disease (Leukemia, Lymphoma, Multiple Myeloma, Others)
5.2.3. By End User (Hospitals, Cancer Treatment Centers)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. Northeast CAR-T Cell Therapy Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Disease
6.2.3. By End User
7. Midwest CAR-T Cell Therapy Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Disease
7.2.3. By End User
8. South CAR-T Cell Therapy Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Disease
8.2.3. By End User
9. West CAR-T Cell Therapy Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Disease
9.2.3. By End User
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. United States CAR-T Cell Therapy Market: SWOT Analysis
13. Competitive Landscape
13.1. Gilead Sciences, Inc (US)
13.1.1. Business Overview
13.1.2. Product & Service Offerings
13.1.3. Recent Developments
13.1.4. Key Personnel
13.1.5. Financials (If Listed)
13.1.6. SWOT Analysis
13.2. Novartis United States
13.3. AbbVie Inc.
13.4. Myriad Genetics
13.5. NeoGenomics Laboratories
13.6. Intellia Therapeutics (US)
13.7. Agilent Technologies, Inc. (US)
13.8. Abcam plc.
13.9. Bio-Techne. (ExoDx)
13.10.Sangamo Therapeutics, Inc. (US)
14. Strategic Recommendations
15. About Us & Disclaimer